ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CTEC Convatec Group Plc

230.60
-2.40 (-1.03%)
21 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Convatec Group Plc LSE:CTEC London Ordinary Share GB00BD3VFW73 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.40 -1.03% 230.60 229.60 229.80 235.40 228.80 233.20 5,367,175 16:35:06
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 2.14B 130.3M 0.0636 36.23 4.78B

Convatec Group PLC Convatec Group PLC: Results of AGM

16/05/2024 5:00pm

RNS Regulatory News


RNS Number : 7990O
Convatec Group PLC
16 May 2024
 

Convatec Group Plc

 

Results of Annual General Meeting

 

London, United Kingdom (16 May 2024) - Poll Result

Convatec Group Plc ("Convatec") held its Annual General Meeting today ("AGM"). The results of the poll held in relation to the resolutions proposed at the AGM are set out below

 


For (see note 2)

Against (see note 2)

Votes Total

(excluding withheld)

% of ISC Voted

Votes Witheld

Resolution

No of shares

%

No of Shares

%


1

To receive the Annual Report and Accounts 2023

      1,852,466,756

100.00%

                   353

0.00%

      1,852,467,109

90.37%

      1,291,713

2

To approve the Directors' Remuneration Report

      1,813,185,796

98.24%

        32,521,511

1.76%

      1,845,707,307

90.04%

      8,051,515

3

To declare Final Dividend

      1,853,744,153

100.00%

              12,049

0.00%

      1,853,756,202

90.44%

            2,620

4

To re-elect Dr John McAdam as a Director

      1,847,283,011

99.65%

          6,442,175

0.35%

      1,853,725,186

90.43%

           33,636

5

To re-elect Karim Bitar as a Director

      1,848,145,807

99.70%

          5,582,073

0.30%

      1,853,727,880

90.44%

           30,942

6

To re-elect Jonny Mason as a Director

      1,848,076,960

99.70%

          5,632,063

0.30%

      1,853,709,023

90.43%

           49,799

7

To re-elect Margaret Ewing as a Director

      1,816,225,341

97.98%

        37,483,741

2.02%

      1,853,709,082

90.43%

           49,740

8

To re-elect Brian May as a Director

      1,846,602,408

99.62%

          7,118,004

0.38%

      1,853,720,412

90.43%

           38,410

9

To re-elect Professor Constantin Coussios as a Director

      1,846,585,982

99.61%

          7,143,987

0.39%

      1,853,729,969

90.44%

           28,853

10

To re-elect Heather Mason as a Director

      1,805,072,326

97.38%

        48,629,636

2.62%

      1,853,701,962

90.43%

           56,860

11

To re-elect Kim Lody as a Director

      1,846,589,957

99.62%

          7,117,950

0.38%

      1,853,707,907

90.43%

           50,915

12

To re-elect Sharon O'Keefe as a Director

      1,846,493,634

99.61%

          7,226,778

0.39%

      1,853,720,412

90.43%

           38,410

13

To re-appoint Deloitte LLP as auditors

      1,851,179,389

99.98%

             440,502

0.02%

      1,851,619,891

90.33%

      2,137,431

14

To authorise the Directors to agree the auditors' remuneration

      1,853,715,114

100.00%

              19,198

0.00%

      1,853,734,312

90.44%

           24,510

15

To approve an amendment to the Company's LTIP rules to reflect the increased maximum award limit set out for executive directors in the Company's prevailing Directors' Remuneration policy.

      1,837,845,100

99.14%

        15,882,668

0.86%

      1,853,727,768

90.44%

           31,054

16

To authorise political donations and political expenditure

      1,836,103,687

99.07%

        17,229,247

0.93%

      1,853,332,934

90.42%

         425,888

17

To authorise the Directors to allot shares

      1,710,658,359

92.28%

      143,073,563

7.72%

      1,853,731,922

90.44%

           26,900

18

To authorise the Directors to disapply pre-emption rights*

      1,711,441,065

92.34%

      142,042,010

7.66%

      1,853,483,075

90.42%

         275,747

 

 

19

 

To authorise the Directors to disapply pre-emption rights in connection with an acquisition or specified capital investment*

      1,664,945,067

90.18%

      181,388,202

9.82%

      1,846,333,269

90.07%

      7,425,553

20

To authorise the Directors to make market purchases of own shares*

      1,850,913,656

99.88%

          2,233,348

0.12%

      1,853,147,004

90.41%

         611,818

21

To authorise the calling of a general meetings on 14 clear days' notice*

      1,795,351,922

96.85%

        58,406,900

3.15%

      1,853,758,822

90.44%

                  0

 

*Special Resolution

NOTES:

1.   All resolutions were passed.

2.   Votes "For" and "Against" are expressed as a percentage of votes received.

3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

4.   Total number of shares in issue is 2,049,789,559 (90.44% of capital was voted).

5.   Computershare acted as scrutineer of the poll on all resolutions.

 

In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business that were passed at the Annual General Meeting have been submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.                      

 

 

 

Enquiries 

 

Ria Banerjee, Group Deputy Company Secretary                                          +44(0)7425 655 845 

 

Cosec@convatec.com  

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92  

 

 

About Convatec 
 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Group revenues in 2023 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE: CTEC). To learn more about Convatec, please visit www.convatecgroup.com

 

 

 

# # #

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGQKABPPBKDFPD

1 Year Convatec Chart

1 Year Convatec Chart

1 Month Convatec Chart

1 Month Convatec Chart

Your Recent History

Delayed Upgrade Clock